Use of Tivolone in the preparation of a medicament for reducing cerebral edema in hemorrhagic stroke

A technology for hemorrhagic stroke, tivolone, applied in the field of medicine

Active Publication Date: 2021-02-02
JINAN UNIVERSITY
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the inventor unexpectedly found that tivolone can reduce the degree of brain edema in hemorrhagic stroke (Intracerebral Hemorrhage, ICH), which has never been found and reported in the prior art

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of Tivolone in the preparation of a medicament for reducing cerebral edema in hemorrhagic stroke
  • Use of Tivolone in the preparation of a medicament for reducing cerebral edema in hemorrhagic stroke

Examples

Experimental program
Comparison scheme
Effect test

experiment example 1

[0015] (1) Animal information

[0016] Experimental procedures on mice were approved by the Weill Cornell Medical Institution Animal Care and Use Committee and were performed in accordance with the National Institutes of Health Guide for the Care and Use of Animal Experiments and ARRIVE (Animal Research: Reports of In Vivo Experiments). Mice were purchased from Charles River Laboratories and maintained at 68°F to 72°F, 30% to 70% humidity, on a 12 hour light-dark cycle with ad libitum access to food (PicoLab Rodent Diet 5053; LabDiet) and water. Male C57BL / 6 mice (8-10 weeks old, 22-25g) were randomly divided into tivolone treatment group and control group. Only vehicle was administered to the control group.

[0017] (2) Gene chip analysis

[0018] The mice in the treatment group received a dose of tivolone (100 mg / kg intraperitoneally) 24 hours before being sacrificed. Total RNA was extracted from mouse brain. Experiments were repeated three times for each treatment group...

experiment example 2

[0024] (1) Animal information

[0025] For animal information, see Experimental Example 1. Male C57BL / 6 mice (8-10 weeks old, 22-25 g) were randomly divided into ICH (cerebral hemorrhage) group (n=6) and ICH+tivolone group (n=5).

[0026] (2) Collagenase-induced hemorrhagic stroke (ICH) model

[0027] Male C57BL / 6 mice (8-10 weeks old) were anesthetized with isoflurane (2-5%) and placed in a stereotaxic stand. During the procedure, the body temperature of the animals was maintained at 37°C using a thermostatic blanket. 1 ml of collagenase (0.075 IU; Sigma) was infused into the right striatum at a flow rate of 0.120 ml / min using a Nanomite syringe pump (Harvard Apparatus) and a Hamilton syringe. Relative to bregma, the stereotaxic coordinates for injections were as follows: lateral, -0.20; anteroposterior, 0.62; and dorsoventral, -0.40. In control animals, 1 ml of physiological saline was perfused. One dose of tivolone (100 mg / kg intraperitoneally) was administered to the ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to the application of tilorone in preparing a medicine for reducing hemorrhagic stroke cerebral edema. Experiments show that the tilorone remarkably upregulates an IFN-related gene in mouse brain. In a collagenase-induced cerebral hemorrhage model, the tilorone obviously reduces the cerebral edema degree of a model mouse. Therefore, the types of application diseases of the tilorone are further enlarged, and new medicine selection is also provided for preventing and treating the cerebral edema of hemorrhagic stroke patients.

Description

technical field [0001] The invention belongs to the technical field of medicine, specifically, the use of tivolone in the preparation of medicines for reducing cerebral edema in hemorrhagic stroke Background technique [0002] Tivolone, also known as diaminofluorenone, chemically named 2,7-bis[2-(diethylamino)ethoxy]-9-fluorenone, is an orally available small molecule interferon inducer , which is also a broad-spectrum antiviral drug, is the first compound among the fluorenone-like drugs to enter clinical research. [0003] At present, studies on the pharmacological effects of tivolone mainly focus on its antiviral, immune induction, antitumor, and antisilicosis effects. For example, Wampler et al. found that tivolone can improve the body's immunity without suppressing the bone marrow. Megel et al. observed that Tivolone is selective for humoral immunity and cellular immunity, and has the function of stimulating B-lymphocytes and exciting macrophages. Munson and Ervin fou...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/138A61P25/00A61P7/10
CPCA61K31/138A61P7/10A61P25/00
Inventor 翟羽佳陈英鑫何蓉蓉拉吉夫·拉坦
Owner JINAN UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap